Keyword: brca



Relevance: High


Strength of Science: Medium-High
Study : Racial and ethnic differences in genetic testing among young breast cancer survivors
Most relevant for: Women diagnosed with breast cancer at age 50 or younger
Genetic testing is recommended for most women who are diagnosed with breast cancer at age 50 or younger. In this study of young women with breast cancer, while the rates of genetic testing did not differ, the rates of women testing positive for an inherited mutation associated with breast cancer did vary between racial and ethnic groups. (2/27/20)
Este artículo está disponible en español.
READ MORE ›


Relevance: High


Strength of Science: High


Research Timeline: Post Approval
Study : Women who exercise have lower breast cancer risk whether or not they have a family history of breast cancer
Most relevant for: Young, high risk women
The effect of physical activity on breast cancer risk was looked at in a study of over 15,000 women. The results suggest that exercise lowers breast cancer risk regardless of family history of breast cancer or menopausal status. (12/6/19)
Este artículo está disponible en español.
READ MORE ›


Relevance: High


Research Timeline: Post Approval
Update : Genetic causes of hereditary pancreatic cancer: BRCA and beyond
Most relevant for: People diagnosed with pancreatic cancer
An update on hereditary pancreatic cancer presented at the annual American Society of Clinical Oncology meeting covered genes and lifetime risk. The update emphasized that all pancreatic cancer patients should be offered genetic counseling and testing. Genetic test results may impact treatment, screening for other cancers and risk to family members. (11/26/19)
READ MORE ›


Relevance: High


Strength of Science: High


Research Timeline: Human Research
Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer
Most relevant for: Women newly-diagnosed with ovarian cancer
This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)
READ MORE ›


Relevance: Medium-High


Strength of Science: Medium-High


Research Timeline: Human Research
Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising
Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation
The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)
READ MORE ›


Relevance: Medium-High


Strength of Science: Medium


Research Timeline: Post Approval
Study : Inherited mutations in metastatic breast cancer patients
Most relevant for: People with metastatic breast cancer
Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)
READ MORE ›


Relevance: High


Strength of Science: High


Research Timeline: Post Approval
Study : Is it safe for BRCA mutation carriers to become pregnant following breast cancer?
Most relevant for: Women with a BRCA mutation who are considering pregnancy after breast cancer
New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies. (9/4/19)
READ MORE ›


Relevance: High


Strength of Science: Medium-High


Research Timeline: Post Approval
Study : MRI or mammograms for detecting breast cancer in families with unknown genetic mutations?
Most relevant for: People with a personal or family history of cancer where no mutation has been found
MRI and mammograms are used together to detect breast cancer in high-risk women who test positive for a BRCA or other gene mutation that increases the risk for breast cancer. For women with a family history of breast cancer but no known genetic mutation, increased screening is recommended. But what method is best? A recent clinical trial in the Netherlands compared MRI and mammography for this population. (8/15/19)
READ MORE ›


Relevance: High


Strength of Science: High


Research Timeline: Human Research
Study : Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.
Most relevant for: People diagnosed with pancreatic cancer who have a BRCA mutation
Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.
The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy. (7/3/19)
READ MORE ›


Relevance: Medium-High


Quality of Writing: Medium-High
Personal Story : A young woman's story of genetic testing and risk-reducing mastectomy
Most relevant for: Young women of color with a BRCA mutation
Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)
Este artículo está disponible en español.
READ MORE ›